Moreover, recent experiments conducted in a humanized immunocompetent mouse model demonstrated that blocking SIGLEC7 or SIGLEC9 reduces tumor burden in vivo, providing support for the use of anti-SIGLEC antibodies as a means to enhance anti-tumor immunity [58]. Here, SIGLEC9 is linked to neoplasm.